Gastrointestinal Neoplasms  >>  Pexa-Vec (pexastimogene devacirepvec)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
NCT01387555 / 2011-000051-16: A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2b
129
US, Canada, Europe, RoW
JX-594 recombinant vaccina GM-CSF, Best Supportive Care
Jennerex Biotherapeutics
Hepatocellular Carcinoma, Liver Cancer, HCC
12/11
12/11
NCT01329809: Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors

Terminated
2a
2
Canada
Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594), JX-594
Jennerex Biotherapeutics
Colorectal Carcinoma
01/12
03/13
NCT00554372: A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

Completed
2
30
US, Canada, RoW
JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
Jennerex Biotherapeutics
Carcinoma, Hepatocellular
12/11
02/13
NCT01171651: A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

Completed
2
25
RoW
JX-594 followed by sorafenib
Jennerex Biotherapeutics
Carcinoma, Hepatocellular
02/13
12/15

Download Options